These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22215409)

  • 1. Insulin glargine: a reevaluation of rodent carcinogenicity findings.
    Stammberger I; Essermeant L
    Int J Toxicol; 2012 Mar; 31(2):137-42. PubMed ID: 22215409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.
    Stammberger I; Bube A; Durchfeld-Meyer B; Donaubauer H; Troschau G
    Int J Toxicol; 2002; 21(3):171-9. PubMed ID: 12055018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to excess insulin (glargine) induces type 2 diabetes mellitus in mice fed on a chow diet.
    Yang X; Mei S; Gu H; Guo H; Zha L; Cai J; Li X; Liu Z; Cao W
    J Endocrinol; 2014 Jun; 221(3):469-80. PubMed ID: 24741073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glargine and cancer: can we now suggest closure?
    Owens DR
    Diabetes Care; 2012 Dec; 35(12):2426-8. PubMed ID: 23173130
    [No Abstract]   [Full Text] [Related]  

  • 5. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
    J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits.
    Hofmann T; Horstmann G; Stammberger I
    Int J Toxicol; 2002; 21(3):181-9. PubMed ID: 12055019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
    Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
    Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
    Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
    Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.